Experimental combo targets rare leukemia

NCT ID NCT04301076

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This early-stage trial tests adding lenalidomide to standard chemotherapy (EPOCH) for adult T-cell leukemia-lymphoma, a rare and aggressive blood cancer linked to HTLV-1 infection. The main goal is to find the safest dose of lenalidomide when used with chemo. Up to 30 adults with certain subtypes of the disease will participate. The study is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lenalidomide
What this could lead to: If it works, this could point toward a more effective treatment for adult T-cell leukemia-lymphoma by combining a targeted drug with standard chemotherapy.
What could go wrong: This is a very early phase 1 trial focused on safety and dosing, not yet testing effectiveness. The study is currently suspended, and the combination may cause significant side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult T-cell leukemia/lymphoma human T-lymphotropic virus 1 infectious disease lymphoma Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ADULT T-CELL LEUKEMIA/LYMPHOMA ADULT T-CELL LEUKEMIA/LYMPHOMA CHRONIC ADULT T-CELL LEUKEMIA/LYMPHOMA HTLV-1 INFECTION

Contacts and locations

Show contact details

Locations

Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone
RECRUITING

New York, New York, 10016, United States

Contact Email: •••••@•••••
Memorial Sloan Kettering Basking Ridge
RECRUITING

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen
RECRUITING

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Memorial Sloan Kettering Commack
RECRUITING

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth
RECRUITING

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau
RECRUITING

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester
RECRUITING

Harrison, New York, 10604, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••
NYP/Weill Cornell Medical Center
RECRUITING

New York, New York, 10065, United States
NYU Langone Hospital - Long Island
RECRUITING

Mineola, New York, 11501, United States

Contact Email: •••••@•••••
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Siteman Cancer Center at Saint Peters Hospital
RECRUITING

City of Saint Peters, Missouri, 63376, United States

Contact Email: •••••@•••••
Siteman Cancer Center at West County Hospital
RECRUITING

Creve Coeur, Missouri, 63141, United States

Contact Email: •••••@•••••
Siteman Cancer Center-South County
RECRUITING

St Louis, Missouri, 63129, United States

Contact Email: •••••@•••••
VCU Massey Comprehensive Cancer Center
RECRUITING

Richmond, Virginia, 23298, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.